The inhibition of VDR by its antagonist blocks PD-L1 expression, reduces the tumor burden in nude mice, and promotes anti-tumor immunity in acute myeloid leukemia, ovarian cancer, and pancreatic cancer [194]. The gene discussed is VDR; the disease is neoplasm.